Shares of Definitive Healthcare Corp. (NASDAQ:DH – Get Free Report) have earned an average recommendation of “Reduce” from the nine ratings firms that are presently covering the stock, Marketbeat reports. Four research analysts have rated the stock with a sell rating, three have assigned a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $2.4714.
DH has been the topic of a number of research analyst reports. Wall Street Zen raised Definitive Healthcare from a “hold” rating to a “buy” rating in a research note on Sunday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Definitive Healthcare in a research note on Wednesday, June 3rd. Zacks Research upgraded Definitive Healthcare from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 28th. Bank of America reiterated an “underperform” rating and set a $0.70 price objective on shares of Definitive Healthcare in a research report on Monday, June 29th. Finally, Robert W. Baird set a $1.10 price objective on Definitive Healthcare in a report on Friday, May 8th.
Read Our Latest Stock Analysis on Definitive Healthcare
Institutional Inflows and Outflows
Definitive Healthcare Trading Up 3.2%
Shares of Definitive Healthcare stock opened at $0.73 on Monday. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.75 and a quick ratio of 1.75. Definitive Healthcare has a 1 year low of $0.62 and a 1 year high of $4.70. The firm has a market cap of $77.03 million, a PE ratio of -0.45, a PEG ratio of 11.41 and a beta of 1.33. The company has a 50 day simple moving average of $0.80 and a two-hundred day simple moving average of $1.21.
Definitive Healthcare (NASDAQ:DH – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of $0.03 by $0.03. The firm had revenue of $55.93 million for the quarter, compared to analyst estimates of $55.02 million. Definitive Healthcare had a negative net margin of 76.04% and a positive return on equity of 4.04%. Definitive Healthcare has set its Q2 2026 guidance at 0.030-0.040 EPS and its FY 2026 guidance at 0.160-0.19 EPS. Analysts expect that Definitive Healthcare will post 0.04 earnings per share for the current fiscal year.
Definitive Healthcare Company Profile
Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.
The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.
Featured Stories
- Five stocks we like better than Definitive Healthcare
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for Definitive Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Definitive Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
